In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 65202-50-8, name is Methyl 6-chloropyridazine-3-carboxylate, introducing its new discovery. name: Methyl 6-chloropyridazine-3-carboxylate
Leukocyte function-associated antigen-1 (LFA-1), also known as CD11a/CD18 or alphaLbeta2, belongs to the beta2 integrin subfamily and is constitutively expressed on all leukocytes. The major ligands of LFA-1 include three intercellular adhesion molecules 1, 2, and 3 (ICAM 1, 2, and 3). The interactions between LFA-1 and the ICAMs are critical for cell adhesion, and preclinical animal studies and clinical data from the humanized anti-LFA-1 antibody efalizumab have provided proof-of-concept for LFA-1 as an immunological target. This article will detail the Structure-activity relationships (SAR) leading to a novel second generation series of highly potent spirocyclic hydantoin antagonists of LFA-1. With significantly enhanced in vitro and ex vivo potency relative to our first clinical compound (1), as well as demonstrated in vivo activity and an acceptable pharmacokinetic and safety profile, 6-((5S,9R)-9-(4-cyanophenyl)-3- (3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro-[4.4]nonan-7-yl) nicotinic acid (2e) was selected to advance into clinical trials.
By the way, if you are interested in learning more fun chemistry with your kids, get your hands into one chemistry set now, and start enjoying the best part of chemistry: experiments about 65202-50-8name: Methyl 6-chloropyridazine-3-carboxylate
Reference：
Pyridazine – Wikipedia,
Pyridazine | C4H4N2441 – PubChem